UPDATE 1-FDA staff question utility of Sanofi diabetes drugs

May 23 (Reuters) - A preliminary review by the U.S. Food and

Drug Administration questioned whether Sanofi SA's

experimental diabetes drug lixisenatide contributed any benefit

to a fixed-dose combination product the company hopes to market.

Read more